Unique ID issued by UMIN | UMIN000032125 |
---|---|
Receipt number | R000036646 |
Scientific Title | Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide). |
Date of disclosure of the study information | 2018/04/06 |
Last modified on | 2019/05/21 13:13:08 |
Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).
Comparison glycemic excursions of Liraglutide with Dulaglutide.
Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).
Comparison glycemic excursions of Liraglutide with Dulaglutide.
Japan |
Type 2 diabetes
Endocrinology and Metabolism |
Others
NO
To compare the glucose-lowering effect and glycemic variability of liraglutide with these of dulaglutide using Flash Glucose monitoring (FGM) in type 2 diabetes mellitus.
Safety,Efficacy
Glycemic control is estimated as the mean blood glucose (MBG).
Intraday glycemic variability is assessed as the standard deviation (SD) and the mean amplitude of glycemic excursions (MAGE).
Hypoglycemia, which is defined as a sensor value of <3.9mmol/L, was also calculated as a total time at <3.9mmol/L.
Hyperglycemia, which is defined as a sensor value of >10.0mmol/L, was also calculated as a total time at >10.0mmol/L.
Interventional
Cross-over
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
The FGM examination is carried out at least 28 days after administering liraglutide. liraglutide is changed to dulaglutide when the first FGM examination end.
The FGM examination is carried out at least 28 days after administering dulaglutide. dulaglutide is changed to liraglutide when the first FGM examination end.
20 | years-old | <= |
Not applicable |
Male and Female
Patients using GLP-1 RAs or the patients who judged a physician to need use of the GLP-1 RAs newly.
Patients with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal) were excluded from this study.
40
1st name | Yasuhiro |
Middle name | |
Last name | Niwa |
Handa City Hospital
Diabetes, Metabolism and Endocrinology
475-8599
2-29, Toyocho, Handa City, Aichi
0569-22-9881
iriri01@goo.jp
1st name | Yasuhiro |
Middle name | |
Last name | Niwa |
Handa City Hospital
Diabetes, Metabolism and Endocrinology
475-8599
2-29, Toyocho, Handa City, Aichi
0569-22-9881
iriri01@goo.jp
Handa City Hospital
Handa City Hospital
Other
Handa City Hospital
2-29, Toyocho, Handa City, Aichi
0569-22-9881
iriri01@goo.jp
NO
2018 | Year | 04 | Month | 06 | Day |
Unpublished
Open public recruiting
2017 | Year | 04 | Month | 01 | Day |
2017 | Year | 11 | Month | 14 | Day |
2017 | Year | 05 | Month | 01 | Day |
2019 | Year | 05 | Month | 01 | Day |
2018 | Year | 04 | Month | 06 | Day |
2019 | Year | 05 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036646
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |